NCT06229093 Multimodal Musical Stimulation for Healthy Neurocognitive Aging
| NCT ID | NCT06229093 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northeastern University |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-12-11 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-12-11 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Stage I randomized, sham-controlled trial on the effects of multimodal musical stimulation on working memory in aging. Neurologically healthy older and younger adults will be tested on working memory and electroencephalography in the first randomized controlled trial of music as a form of brain stimulation, with multimodal musical stimulation and control stimulation conditions. Results will test the causal role of oscillatory mechanisms of the brain on cognition, and will lay the groundwork to the first musical, neurophysiologically targeted, brain-stimulation device for reversing cognitive decline in aging.
Eligibility Criteria
Inclusion Criteria: * normal or corrected-to-normal vision * no more than mild hearing loss * no recent history of neurological or psychiatric disorders, including mood disorders or use of medications that may affect cognition or responsiveness to music. Exclusion Criteria: * moderate or severe hearing loss (40+ dB) * visual impairment (including color blindness) that cannot be corrected with glasses or contacts * recently changed dosage of cholinesterase inhibitors or psychotropic medication * recent history of psychotic or schizophrenic episodes * major neurologic diagnosis or other condition that might impair cognition or confound assessments (dementia, ADRD; Parkinson's disease, stroke, brain injury, epilepsy, or recent cardiovascular or neurovascular event) * recent history of serious physical trauma or diagnosis of serious chronic health condition requiring medical treatment and monitoring .
Contact & Investigator
Psyche Loui, PhD
PRINCIPAL INVESTIGATOR
Northeastern University
Frequently Asked Questions
Who can join the NCT06229093 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 95 Years, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06229093 currently recruiting?
Yes, NCT06229093 is actively recruiting participants. Contact the research team at c.parrish@northeastern.edu for enrollment information.
Where is the NCT06229093 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06229093 clinical trial?
NCT06229093 is sponsored by Northeastern University. The principal investigator is Psyche Loui, PhD at Northeastern University. The trial plans to enroll 100 participants.